Synthetic Dendritic Cell Mimics for Immune Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Dendritic cells, crucial for immune activation, are rare and difficult to isolate, hindering therapeutic applications.

Innovation Solution

A device comprising a delivery vehicle with a scaffold composition and compounds such as adjuvants and antigens, including PEI, to modulate the immune response by enhancing antigen presentation and immune cell activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If dendritic cells are used for therapeutic immune activation, then immune response enhancement is achieved, but isolation difficulty and rarity of dendritic cells hinder therapeutic application

Engineering Contradiction:

Improveimmune response enhancementVSAvoidisolation difficulty

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses synthetic dendritic cell mimics as intermediary structures that replicate the immune-activating function of natural dendritic cells without requiring their isolation. These mimics serve as mediators between the antigen and the immune system, providing the therapeutic benefit while avoiding the practical difficulties of working with rare natural dendritic cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates synthetic copies of dendritic cells - nanoscale structures that replicate the key functional aspects of natural dendritic cells. These synthetic dendritic cell mimics copy the ability to present antigens and activate immune responses, thereby achieving the therapeutic effect without needing to isolate and manipulate actual dendritic cells.

Inventive Principle:

Principle #26Copying

2Reliability

If complex delivery vehicles are used to enhance antigen presentation, then immune cell activation is improved, but device complexity increases

Engineering Contradiction:

Improveantigen presentation efficiencyVSAvoiddelivery vehicle structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs porous silica nanoparticles as the delivery vehicle structure. The porous architecture provides high surface area for antigen loading and facilitates immune cell interaction, achieving enhanced antigen presentation through the inherent properties of porous materials rather than through complex engineered mechanisms.

Inventive Principle:

Principle #31Porous materials

Solution Approach 2:

The delivery vehicle is constructed as a composite material system combining silica nanoparticle core with surface-modified components. This composite structure integrates multiple functions (antigen loading, immune cell targeting, adjuvant delivery) into a single integrated platform, reducing overall system complexity while maintaining high antigen presentation efficiency.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS12274744B2Biomaterials for modulating immune responses

Publication Date: 2025.04.15 PRESIDENT & FELLOWS OF HARVARD COLLEGE

AI summary

The provided herein are methods and compositions for eliciting an immune response to an antigen, such as cancer and microbial antigens.